设计药物
吲唑
合成大麻素
药理学
化学
大麻酚
大麻素
医学
药品
立体化学
大麻
生物化学
精神科
受体
作者
Nahoko Uchiyama,Satoru Matsuda,Maiko Kawamura,Yoshihiko Shimokawa,Ruri Kikura‐Hanajiri,Kosuke Aritake,Yoshihiro Urade,Yukihiro Goda
标识
DOI:10.1016/j.forsciint.2014.03.013
摘要
Our continuous survey of illegal products in Japan revealed the new distribution of 15 designer drugs. We identified four synthetic cannabinoids, i.e., NNEI (1), 5-fluoro-NNEI (2), 5-chloro-NNEI (3) and NNEI indazole analog (4), and seven cathinone derivatives, i.e., MPHP (5), α-PHPP (6), α-POP (7), 3,4-dimethoxy-α-PVP (8), 4-fluoro-α-PVP (9), α-ethylaminopentiophenone (10) and N-ethyl-4-methylpentedrone (11). We also determined LY-2183240 (12) and its 2'-isomer (13), which were reported to inhibit endocannabinoid uptake, a methylphenidate analog, 3,4-dichloromethylphenidate (14), and an MDA analog, 5-APDB (15). No chemical and pharmaceutical data for compounds 3, 4, 6 and 7 had been reported, making this the first report on these compounds.
科研通智能强力驱动
Strongly Powered by AbleSci AI